Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD

• Published in: Alzheimer's & dementia Vol. 16; no. S9
• Main Authors: Bateman, Randall J, Aschenbrenner, Andrew J., Benzinger, Tammie L.S., Clifford, David, Coalier, Kelley, Cruchaga, Carlos, Fagan, Anne M., Farlow, Martin R., Goate, Alison M., Gordon, Brian A., Hassenstab, Jason, Jack, Clifford R., Koeppe, Robert A., McDade, Eric, Mills, Susan, Morris, John C., Salloway, Stephen P., Santacruz, Anna, Snyder, Peter J., Wang, Guoqiao, Xiong, Chengjie, Snider, B. Joy, Mummery, Catherine J., Surti, Ghulam M., Hannequin, Didier, Wallon, David, Berman, Sarah, Lah, James J., Jiménez‐Velazquez, Ivonne Z., Roberson, Erik D., Dyck, Christopher H., Honig, Lawrence S., Sanchez‐Valle, Raquel, Brooks, William S., Gauthier, Serge, Masters, Colin L., Galasko, Doug R., Brosch, Jared R., Hsiung, Ging‐Yuek Robin, Jayadev, Suman, Formaglio, Maïté, Masellis, Mario, Clarnette, Roger, Pariente, Jeremie, Dubois, Bruno, Pasquier, Florence, Andersen, Scott W., Holdridge, Karen C., Mintun, Mark A., Sims, John R., Yaari, Roy, Baudler, Monika, Delmar, Paul, Doody, Rachelle, Fontoura, Paulo, Kerchner, Geoffrey A.
• Format: Journal Article
• Language: English
• Published: 01.12.2020

Abstract Background Alzheimer’s disease (AD) prevention trials aim to intervene prior to significant neuronal loss, brain damage, and symptom onset to delay or slow cognitive decline. In dominantly inherited AD (DIAD), mutation carriers develop symptomatic AD at predictable ages with near 100% penet...